Phase ιι (window) preoperative study of olaparib with cisplatin or with durvalumab or alone or no treatment in patients with histologically proven head and neck squamous cell carcinoma who are candidates for surgery (OPHELIA).

Amanda Psyrri,George Papaxoinis,Panagiota Economopoulou,Ioannis Kotsantis,Vassiliki Kotoula,Onoufrios Tsavaris,Chrysanthi Avgerinou,George Fountzilas

Phase ιι (window) preoperative study of olaparib with cisplatin or with durvalumab or alone or no treatment in patients with histologically proven head and neck squamous cell carcinoma who are candidates for surgery (OPHELIA).

2017

Amanda Psyrri
George Papaxoinis
Panagiota Economopoulou
Ioannis Kotsantis
Vassiliki Kotoula
Onoufrios Tsavaris
Chrysanthi Avgerinou
George Fountzilas

TPS6096Background: Novel agents are often investigated in unselected end-stage cancer patients and their efficacy is evaluated by the classical RECIST criteria making unlikely to fully exploit the ...

Keywords:

Head and neck squamous-cell carcinoma
Pathology
Cisplatin
Durvalumab
Olaparib
General surgery
Medicine
Oncology
in patient
Internal medicine
Cancer
novel agents

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations